Advanced Filters
noise

Discoid Lupus Erythematosus Clinical Trials

A listing of Discoid Lupus Erythematosus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 286 clinical trials

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

The Polish multicentre observational (non-interventional) study aiming to collect data on the characteristic of patients with systemic lupus erythematosus and clinical outcomes of anifrolumab administered in the scope of routine clinical practice.

18 years of age All Phase N/A
Y Yuqi Zhang

Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus

To investigate biomarkers to identify pediatric SR-SLE patients by non-invasive echocardiographic techniques.

7 - 17 years of age All Phase N/A
M Marc Scherlinger, Investigator

ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS

Blood platelets, well known for their role in hemostasis, are abnormally activated in patients suffering from systemic lupus erythematosus (SLE), but also from other immunomediated diseases (scleroderma, vasculitis, myositis, Gougerot-Sjögren's and rheumatoid arthritis) in cases of high disease activity. Once activated, platelets express adhesion molecules such as P-selectin on their …

18 - 70 years of age All Phase N/A
K Kai Sun

Intervention to Improve Communication and Medication Adherence in Lupus

CO-LEAD is an intervention to improve patient-provider communication and medication adherence among patients with systemic lupus erythematosus (SLE). The purpose of this study is to optimize the culturally appropriate delivery and test the effect of the CO-LEAD intervention, which includes the following: clinicians will be provided with a program to …

18 - 90 years of age All Phase N/A

A Study of E6742 in Participants With Systemic Lupus Erythematosus

The main purpose of the study is to demonstrate the efficacy based on dose response of E6742 compared with placebo as defined by the proportion of participants achieving a response using the British Isles Lupus Assessment Group (BILAG) based Composite Lupus Assessment (BICLA) with a low dose of oral corticosteroids …

18 - 75 years of age All Phase 2

BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus

This phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus erythematosus (SLE). It is hypothesized that BAFF CAR-T cells will be safe and will improve SLE disease activity scores.

18 - 65 years of age All Phase 1
D Desmond Yap, MD

SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease

Lupus nephritis (LN) is a common manifestation in patients with systemic lupus erythematosus (SLE), and is an important cause of acute kidney injury and chronic kidney disease (CKD). Although the standard-of-care treatments for active severe LN are effective, a substantial proportion of LN patients still develop CKD and eventually end-stage …

18 years of age All Phase 2
D Dhriti Sharma

Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus

This study aims to investigate the feasibility and effectiveness of a cognitive behavioral coping skills program, Treatment and Education Approach for Childhood-onset Lupus (TEACH), for youth with cSLE when integrated into medical care. This TEACH program aims to teach participants skills in order to cope with fatigue, pain, and depressive …

12 - 22 years of age All Phase N/A
H Hui Luo

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis

18 - 70 years of age All Phase 1/2

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of YK012 in participants with Moderate to Severe Systemic Lupus Erythematosus (SLE).

18 - 75 years of age All Phase 1/2

Simplify language using AI